Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19
Komissarov et al.,
Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19,
medRxiv, doi:10.1101/2020.06.30.20143289 (Preprint)
Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 patients, showing no significant differences (significant reduction in viral load is seen in both groups).
The groups are not comparable, with significant differences seen between hospitalized and non-hospitalized patients. 9 of 10 hospitalized patients were in the HCQ group and only one in the control group. 2 additional control patients were added between the first and second version of this preprint (including the only hospitalized control patient).
risk of viral load, 25.0% higher, RR 1.25, p = 0.45, treatment 26, control 10.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Komissarov et al., 30 Jun 2020, retrospective, Russia, preprint, 8 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.30.20143289; this version posted September 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form
of COVID-19
Alexey Komissarov1,2, Ivan Molodtsov1,3, Oxana Ivanova1,2, Elena Maryukhnich1,2, Svetlana
Kudryavtseva1, Alexey Mazus4, Evgeniy Nikonov5, Elena Vasilieva1,2*
1
Clinical City Hospital named after I.V. Davydovsky, Moscow Department of Healthcare,
Moscow, Russia.
2
Laboratory of Atherothrombosis, Cardiology Department, Moscow State University of Medicine
and Dentistry, Moscow, Russia.
3
N.F. Gamaleya Federal National Research Centre for Epidemiology and Microbiology, Moscow,
Russia.
4
Moscow City Center for AIDS Prevention and Control, Moscow Department of Healthcare,
Moscow, Russia.
5
Moscow Department of Healthcare, Moscow, Russia.
Abstract
Due to the constantly growing numbers of COVID-19 infections and death cases attempts were
undertaken to find drugs with anti SARS-CoV-2 activity among ones already approved for other
pathologies. In the framework of such attempts, in a number of in vitro, as well as in vivo, models it
was shown that hydroxychloroquine (HCQ) has an effect against SARS-CoV-2. While there was
not enough clinical data to support the use of HCQ, several countries including Russia have
included HCQ in treatment protocols for infected patients and for prophylactic. Here, we evaluated
the SARS-CoV-2 RNA in nasopharynx swabs from infected patients in mild conditions and
compared the viral RNA load dynamics between patients receiving HCQ and control group without
antiviral pharmacological therapy. We found statistically significant relationship between maximal
RNA quantity and patients’ deteriorating medical conditions, as well as confirmed the arterial
hypertension to be a risk factor for people with COVID-19. However, we showed that HCQ therapy
neither shortened the viral shedding period nor reduced the virus RNA load.
Keywords: COVID-19, SARS-CoV-2, hydroxychloroquine, quantitative PCR with reverse
transcription, viral load
*Corresponding
author:
Elena that
Vasilieva,
MD,
PhD,
Clinical
City
Hospital
named
after I.V.
NOTE: This preprint reports
new research
has not been
certified
by peer
review and
should
not be used
to guide clinical
practice.
Davydovsky, 11 Yauzskaya Street, Moscow, Russia, 109240. E-mail: vasilievahelena@gmail.com
medRxiv preprint doi: https://doi.org/10.1101/2020.06.30.20143289; this version posted September 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-ND 4.0 International license .
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit